scispace - formally typeset
P

Peter J. O'Dwyer

Researcher at University of Pennsylvania

Publications -  372
Citations -  32780

Peter J. O'Dwyer is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 71, co-authored 337 publications receiving 29572 citations. Previous affiliations of Peter J. O'Dwyer include National Institutes of Health & Royal Perth Hospital.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Inhibition of mutated, activated BRAF in metastatic melanoma.

Keith T. Flaherty, +10 more
- 25 Aug 2010 - 
TL;DR: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.
Journal ArticleDOI

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Bruce J. Giantonio, +7 more
- 20 Apr 2007 - 
TL;DR: The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal cancer.
Journal ArticleDOI

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Gregory L. Beatty, +12 more
- 25 Mar 2011 - 
TL;DR: These findings demonstrate a CD40-dependent mechanism for targeting tumor stroma in the treatment of cancer and demonstrate that cancer immune surveillance does not necessarily depend on therapy-induced T cells; rather, it is shown that tumor regression required macrophages but not T cells or gemcitabine.
Journal ArticleDOI

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Andrew K. Godwin, +5 more
- 01 Apr 1992 - 
TL;DR: In this paper, exposure of human ovarian tumor cell lines to cisplatin led to development of cell lines that exhibited increasing degrees of drug resistance, which were closely correlated with increase of the levels of cellular glutathione.